New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Aligos Therapeutics, Inc. (ALGS) vs NKGen Biotech, Inc. (NKGN)

Aligos Therapeutics, Inc. and NKGen Biotech, Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. and NKGen Biotech, Inc. are of similar size ($8.8M and $8.8M). Across the 8 metrics below, Aligos Therapeutics, Inc. leads on 5 and NKGen Biotech, Inc. on 3.

Valuation

Metric ALGS NKGN Biotechnology median
P/E n/m n/m 8.49
P/S 0.39 — 8.56
P/B 1.15 n/m 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.26 n/m 0.69
EV/Sales (0.56) — 8.00
Earnings yield (512.10%) (10,600.00%) (35.81%)
Free cash flow yield (529.27%) (4,296.38%) (25.41%)

Profitability

Metric ALGS NKGN Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (215.55%) — 0.00%
Net margin (197.01%) — 0.00%
Free cash flow margin (204.07%) — 0.00%
Return on equity (159.46%) 44.70% (51.58%)
Return on assets (84.46%) (146.49%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALGS NKGN Biotechnology median
Revenue growth (TTM) 1,171.58% — 7.20%
EPS growth (last fiscal year) 88.30% 71.38% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ALGS NKGN Biotechnology median
Debt to equity 0.00 (0.59) 0.00
Current ratio 1.77 0.05 4.79
Net debt to EBITDA 0.87 (1.69) 1.01

Dividend

Metric ALGS NKGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALGS NKGN Biotechnology median
Market cap 8.81m 8.76m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack